Clinical Trials Logo

Clinical Trial Summary

Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.


Clinical Trial Description

A multicenter, single-arm phase II, open-label study, to evaluate the efficacy and safety of pembrolizumab 400 mg Q6W in combination with lenvatinib 20 mg QD in patients with recurrent, persistent, metastatic or locally advanced VSCC not amenable to salvage surgery or definitive (chemo)radiation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05903833
Study type Interventional
Source AGO Research GmbH
Contact Yvonne Treffner, Dr
Phone +4920195981217
Email ytreffner@ago-ovar.de
Status Not yet recruiting
Phase Phase 2
Start date January 1, 2024
Completion date January 1, 2029

See also
  Status Clinical Trial Phase
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01079832 - Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Phase 2
Completed NCT00335998 - Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies Phase 1
Terminated NCT03277482 - Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Phase 1
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1
Withdrawn NCT01313104 - Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer N/A